Eric Connor joined Circle Pharma as a Senior Director of CMC (Chemistry, Manufacturing and Controls). Prior to joining Circle Pharma, Dr. Connor served as Senior Director, CMC at Boundless Bio, where he spearheaded CMC development for two innovative programs. Before Boundless Bio, Dr. Connor functioned as Director of CMC Small Molecule at Arcus Biosciences, where he incorporated key innovations into CMC development and manufacturing. At MyoKardia, he served as an Associate Director Chemical Development, playing a role in the transformative Camzyos™ (mavacamten) project. Prior to MyoKardia, Dr. Connor contributed to Relypsa’s success, leading chemistry on a project from a research stage to NDA acceptance (Veltassa®, NDA Application 2014, approved 2016). He is listed on 27 U.S.-issued patents. Dr. Connor earned his B.S. and Ph.D. in chemistry from University College Dublin, Ireland and further enriched his academics with a chemistry postdoctoral fellowship at Caltech in Pasadena, California. Dr. Connor’s commitment to execution of complex CMC projects, led him to earn a Project Management Professional certification in 2016 from the Project Management Institute.